

Norway-Vadsø: Laboratory reagents

OJ S 209/2023 30/10/2023

Contract notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1. Name and addresses

Official name: SYKEHUSINNKJØP HF

National registration number: 916879067

Postal address: Postboks 40

Town: VADSØ

NUTS code: NO Norge

Postal code: 9811

Country: Norway

Contact person: Postmottak Sykehusinnkjøp

E-mail: post@sykehusinnkjop.no

Telephone: +47 78950700

Internet address(es):

Main address: <https://permalink.mercell.com/214858782.aspx>

Address of the buyer profile: <http://www.sykehusinnkjop.no/>

I.2. Information about joint procurement

The contract is awarded by a central purchasing body

I.3. Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: <https://permalink.mercell.com/214858782.aspx>

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: <https://permalink.mercell.com/214858782.aspx>

I.4. Type of the contracting authority

Body governed by public law

I.5. Main activity

Health

Section II: Object

II.1. Scope of the procurement

II.1.1. Title

Monitoring of the drugs adalimumab, infliximab and rituximab; serum concentration and antibody tests for Bergen Hospital Trust

Reference number: 2023/1429

II.1.2.

Main CPV code

33696500 Laboratory reagents

II.1.3. Type of contract

Supplies

II.1.4. Short description

Framework agreement for the purchase of tests for measuring the concentrations of and antibodies directed against the drugs Adalimumab, Infliximab and Rituximab in human serum.

II.1.5. Estimated total value

Value excluding VAT: 6 750 000,00 NOK

II.1.6. Information about lots

This contract is divided into lots: no

II.2. Description**II.2.2. Additional CPV code(s)**

33690000 Various medicinal products

II.2.3. Place of performance

NUTS code: NO0A2 Vestland

II.2.4. Description of the procurement

The purpose of the procurement is to enter into a framework agreement for the purchase of tests for measuring the concentration of and antibodies directed against the drugs Adalimumab, Infliximab and Rituximab in human serum in patients with autoimmune inflammatory diseases (such as arthritis, Chron's disease, ulcerative colitis, psoriasis and multiple sclerosis (MS)).

The analyses are part of disease monitoring, where drug concentrations are monitored and the formation of unwanted antibodies (immunogenicity) is identified, which can lead to loss of effect and increase the risk of infusion reactions.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value

Value excluding VAT: 6 750 000,00 NOK

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 03/01/2024 End: 03/01/2028

This contract is subject to renewal: yes

Description of renewals:

Option to extend the contract for one year + one year.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: yes

Description of options:

Tests for other biologics that can be delivered.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Section III: Legal, economic, financial and technical information

III.1. Conditions for participation

III.1.1. Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

Tenderers must be registered in a company register or a trade register in the country where the tenderer is established.

Documentation Requirement: Norwegian tenderers: Company Registration Certificate

Foreign companies: Verification that the tenderer is registered in a professional register in the country where the tenderer is established.

III.1.2. Economic and financial standing

List and brief description of selection criteria:

Tenderers must have sufficient economic and financial capacity to fulfil the contractual obligations.

Economic and financial capacity means that the Tenderer fulfils the following requirements:

A credit rating of at least score A or higher, measured against the AAA Soliditet's score or an equivalent score from another reputable credit rating agency.

Minimum level(s) of standards possibly required:

The contracting authority will evaluate the tenderer's compliance with the qualification requirements in the following manner:

Credit rating

If a tenderer has valid reasons for not being able to provide the documentation requested by the contracting authority, the tenderer can prove his economic and financial capacity with another document, including for example a parent company guarantee, bank guarantee, etc.

The contracting authority reserves the right to obtain a rating report from www.solidtet.no (delivered by Bisnode Credit AS/Dun & Bradstreet) to verify that a tenderer has sufficient economic and financial ability to comply with the contract obligations.

III.1.3. Technical and professional ability

List and brief description of selection criteria:

N/A

Minimum level(s) of standards possibly required:

N/A

Section IV: Procedure

IV.1. Description

IV.1.1. Type of procedure

Open procedure

IV.1.3. Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with a single operator

In the case of framework agreements, provide justification for any duration exceeding 4 years:

Changing the method involves major reorganisations in the routine operations of the laboratory. Verification of a new method is extensive and resource-intensive, both in terms of time and personnel. Changing the method would also entail reduced patient safety due to increased response time during the transition as well as an increased risk of incorrect responses during the transition between the old and new method.

See the complete justification in the Contest Provisions.

IV.1.8. Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2. Administrative information

IV.2.2. Time limit for receipt of tenders or requests to participate

Date: 24/11/2023 Local time: 12:00

IV.2.3. Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4. Languages in which tenders or requests to participate may be submitted

Norwegian

IV.2.6. Minimum time frame during which the tenderer must maintain the tender

Duration in months: 6 (from the date stated for receipt of tender)

IV.2.7. Conditions for opening of tenders

Date: 24/11/2023 Local time: 12:00

Section VI: Complementary information

VI.1. Information about recurrence

This is a recurrent procurement: no

VI.2. Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3. Additional information

VI.4. Procedures for review

VI.4.1. Review body

Official name: Øst-Finnmark tingrett

Postal address: Postboks 54

Town: Vadsø

Postal code: 9811

Country: Norway

E-mail: ost-finnmark.tingrett@domstol.no

Telephone: +47 78786450

VI.5. Date of dispatch of this notice

25/10/2023

